Emre Mert Ipekoglu

Emre Mert Ipekoglu

Auto-generated profile, based on publicly available information

Emre Mert Ipekoglu

Department of Biological Sciences, Middle East Technical University, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2021 in Allergy
Verified
Journal Article
Open access
PDF file
IYIsmail Cem Yilmaz
Ismail Cem Yilmaz
EIEmre Mert Ipekoglu
Emre Mert Ipekoglu
ABArtun Bulbul
Artun Bulbul
NTNilsu Turay
Nilsu Turay
MYMuzaffer Yildirim
Muzaffer Yildirim
MGMayda Gursel
Mayda Gursel
Background: Vaccines that incorporate multiple SARS‐CoV‐2 antigens can further broaden the breadth of virus‐specific cellular and humoral immunity. This study describes the development and immunogenicity of SARS‐CoV‐2 VLP vaccine that incorporates the four structural proteins of SARS‐CoV‐2.Methods: VLPs were generated in transiently transfected HEK293 cells, purified by multimodal chromatography, and characterized by tunable‐resistive pulse sensing, AFM, SEM, and TEM. Immunoblotting studies verified the protein identities of VLPs. Cellular and humoral immune responses of immunized animals demonstrated the immune potency of the formulated VLP vaccine.Results: Transiently transfected HEK293 cells reproducibly generated vesicular VLPs that were similar in size to and expressing all four structural proteins of SARS‐CoV‐2. Alum adsorbed, K3‐CpG ODN‐adjuvanted VLPs elicited high titer anti‐S, anti‐RBD, anti‐N IgG, triggered multifunctional Th1‐biased T‐cell responses, reduced virus load, and prevented lung pathology upon live virus challenge in vaccinated animals.Conclusion: These data suggest that VLPs expressing all four structural protein antigens of SARS‐CoV‐2 are immunogenic and can protect animals from developing COVID‐19 infection following vaccination.

30 November 2016 in Journal of Basic Microbiology
Verified
Journal Article
Closed access
PDF file
EIEmre M. Ipekoğlu
Emre M. Ipekoğlu
KGKoray Göçmen
Koray Göçmen
MÖMehmet T. Öz
Mehmet T. Öz
MGMuazzez Gürgan
Muazzez Gürgan
MYMeral Yücel
Meral Yücel

8 August 2024 in Immunological Investigations
Verified
Journal Article
Closed access
PGPınar Gür-Çetinkaya
Pınar Gür-Çetinkaya
IAIrem Fatma Abras
Irem Fatma Abras
IEIrem Evcili
Irem Evcili
TYTugçe Yildirim
Tugçe Yildirim
YCYasemin Ceylan
Yasemin Ceylan
IGIhsan Gursel
Ihsan Gursel
Background The COVID-19 pandemic has caused significant morbidity and mortality globally. The role of plasma-derived extracellular vesicles (EVs) in pediatric COVID-19 patients remains unclear. Methods We isolated EVs from healthy controls (n = 13) and pediatric COVID-19 patients (n = 104) with varying severity during acute and convalescent phases using serial ultracentrifugation. EV effects on healthy PBMCs, na & iuml;ve CD4+ T cells, and monocytes were assessed through in vitro assays, flow cytometry, and ELISA. Results Our findings indicate that COVID-19 severity correlates with diverse immune responses. Severe acute cases exhibited increased cytokine levels, decreased IFN gamma levels, and lower CD4+ T cell and monocyte counts, suggesting immunosuppression. EVs from severe acute patients stimulated healthy cells to express higher PDL1, increased Th2 and Treg cells, reduced IFN gamma secretion, and altered Th1/Th17 ratios. Patient-derived EVs significantly reduced proinflammatory cytokine production by monocytes (p < .001 for mild, p = .0025 for severe cases) and decreased CD4+ T cell (p = .043) and monocyte (p = .033) populations in stimulated healthy PBMCs. Conclusion This study reveals the complex relationship between immunological responses and EV-mediated effects, emphasizing the impact of COVID-19 severity. We highlight the potential role of plasma-derived EVs in early-stage immunosuppression in severe COVID-19 patients.